Zerbib F, Bruley des Varannes S, Oriola R C, McDonald J, Isal J P, Galmiche J P
Laboratory Fonctions Digestives et Nutrition, Hôpital Laënnec, Nantes, France.
Aliment Pharmacol Ther. 1994 Aug;8(4):403-7. doi: 10.1111/j.1365-2036.1994.tb00307.x.
The effect of alosetron, a new specific 5-HT3 receptor antagonist, on the visceral perception in response to gastric distension was assessed in 12 healthy male subjects in a randomized, double-blind, placebo controlled crossover trial.
Each subject was given orally either alosetron 1 mg b.d. or placebo b.d. for 6 days (wash-out period 7-28 days). At the end of each dosing period, both isobarometric and isovolumetric gastric distensions were performed using an electronic barostat.
Alosetron did not modify the gastric wall compliance (pressure-volume relationship). Alosetron had an effect similar to placebo on the visceral perception scores in both isobarometric and isovolumetric distensions. The mean (+/- SEM) thresholds for abdominal discomfort were, respectively, 16.8 +/- 0.7 mmHg and 825 +/- 61 mL with alosetron, 16.7 +/- 0.6 mmHg and 883 +/- 45 mL with Placebo (P = NS).
5-HT3 receptors do not appear to be involved in the visceral perception of gastric distension in healthy subjects.
在一项随机、双盲、安慰剂对照的交叉试验中，对12名健康男性受试者评估了新型特异性5 - HT3受体拮抗剂阿洛司琼对胃扩张时内脏感觉的影响。
每位受试者口服阿洛司琼1毫克，每日两次或安慰剂，每日两次，共6天（洗脱期7 - 28天）。在每个给药期结束时，使用电子恒压器进行等压和等容胃扩张。
阿洛司琼未改变胃壁顺应性（压力 - 容积关系）。在等压和等容扩张中，阿洛司琼对内脏感觉评分的影响与安慰剂相似。阿洛司琼组腹部不适的平均（±标准误）阈值分别为16.8±0.7 mmHg和825±61 mL，安慰剂组为16.7±0.6 mmHg和883±45 mL（P = 无显著性差异）。
5 - HT3受体似乎不参与健康受试者胃扩张的内脏感觉。
